Nanobiotix (NBTX) announced the expiration of the waiting period under the Hart-Scott-Rodino, or HSR, Antitrust Improvements Act of 1976 for its previously announced global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), or JNJ, for the investigational, potential radioenhancer NBTXR3. With the expiration of the HSR waiting period, the transaction has become effective, and as such, Nanobiotix is eligible to receive payment of the $30M upfront cash licensing fee.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBTX:
- NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3
- NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023
- Voting Rights and Shares Capital of the Company
- Nanobiotix; 1st patient injected in study evaluating activated NBTXR3 for cancer
- NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers